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Table	1.1	Bacteria	associated	with	the	development	of	neurodegenerative	disorders.	Neurodegenerative	Disorder	 Bacteria	with	Probable	Associations	 Sources	Amyotrophic	lateral	sclerosis	 Borrelia	burgdorferi	(Lyme	disease),	Chlamydia	pneumoniae,	Mycoplasma	spp.	 [12-16]	Alzheimer’s	disease	 Borrelia	burgdorferi,	Chlamydia	pneumoniae,	Mycoplasma	spp.,	Helicobacter	pylori	 [17-41]	Multiple	Sclerosis	 Borrelia	burgdorferi,	Chlamydia	pneumoniae,	Mycoplasma	
spp.	 [42-49]	Parkinson’s	disease	 Chlamydia	pneumoniae,	Helicobacter	pylori,	Nocardia	asteroides,	Bordetella	pertussis	 [50-64]		
Bacterial	Toxins:	Understanding	the	Role	of	Lipopolysaccharides	Beyond	direct	infection,	some	bacteria	are	capable	of	generating	non-infectious,	bioactive	toxins	that	are	independently	capable	of	inducing	an	immune	response	without	the	presence	of	living	bacteria.		In	the	late	19th	Century,	Pfeiffer	discovered	that	heat-inactivated	Vibrio	cholerae	could	still	induce	fever	when	administered	to	guinea	pigs	[65].		Since	then	these	bacterial	toxins	have	been	classified	as	either	exotoxins	or	endotoxins.	Exotoxins	are	usually	highly	toxic	secreted	proteins	generated	by	a	living	bacterium,	while	endotoxins	are	usually	lipid	components	released	from	the	outer	membrane	of	a	dead	or	phagocytized	bacterium.		Exotoxins	such	as	botulism	and	tetanus	have	long	been	recognized	as	direct	neurotoxins	(pathogenic	regardless	of	the	host’s	immune	response).		On	the	other	hand,	endotoxins	are	only	pathogenic	through	a	severe	immune	response—a	condition	known	as	endotoxemia.		Although	endotoxins	are	produced	by	both	Gram-positive	and	Gram-negative	bacteria,	varying	greatly	among	bacterial	species	and	strains,	human	cases	of	endotoxemia	are	primarily	derived	from	the	lipopolysaccharide	(LPS)	on	membrane	fragments	from	Gram-negative	bacterial	infections	[66-68].		Nearly	seven	decades	of	research	establishing	our	current	understanding	of	the	immune	system	and	cytokine	signaling	has	enabled	us	to	understand	that	the	pathological	effects	of	LPS	are	indirect.		LPS	is	thought	to	mediate	its	indirect	toxicity	by	initiating	a	cascade	of	host-generated	factors	such	as	prostaglandins,	cytokines	(e.g.	IL-1,	IL-6	and	TNF	-α),	nitric	oxide,	superoxide,	vasoactive	amines,	proteases	(e.g.	matrix	metalloproteinases)	and	products	of	the	complement	and	coagulation	cascades	that	are	





































































































































































Astrocyte	‘Enrichment’	Method	Details	 Purity	 Source	Shake-off	method	 90-96%	 [243]	Shake-off	method	with	2-4	passages	 95-98%	 [244]	Shake-off	method	with	AraC	after	confluence	 90-98%	 [245]	Shake-off	method	with	LME	 96-98%	 [246]	Shake-off	method	with	AraC	and	LME	 >99%	 [247]	Shake-off	method	with	liposomal	clodronate	 >99%	 [248]	Vigorous	wash	method	 >99%	 [249]	Discontinous	percoll	gradient	method	 98%	 [250]	FAC	Sorting	 98%	 [251]	MAC	Sorting	 95%	 [242,	252]	Shake-off	method	with	saporin	 >99%	 [253]	Neural	stem	cell	differentiation	 >99%	 [254]	Genetic	Microglial	Ablation	 ~100%	 [237]	Immunopanning	method	 >99%	 [255]	Genetic	Conditional	Microglial	Ablation	 >99%	 [220]	

























Primary	Rat	Cortical	Astrocytes	 +	 +	 NA	 [262]	Primary	Rat	Cortical	Astrocytes	 (-)	 +	 NA	 [263]	Primary	Mouse	Whole	Brain	Astrocytes		 +	 +	 NA	 [264]	Secondary	Rat	Cortical	Astrocytes		 (-)	 +	 NA	 [265]	Primary	Mouse	Cortical	Astrocytes	 +	 -	 -	 [266]	Secondary	Rat	Cortical	Astrocytes	 (-)	 +	 NA	 [267]	Secondary	Human	Fetal	Whole	Brain	Astrocytes		 (-)	 -	 NA	 [268]	Primary	Rat	Cortical	Astrocytes		 +	 +	 NA	 [269]	Secondary	Human	Fetal	and	Adult	Whole	Brain	Astrocytes	 +	 +	 +/-	 [270]	Primary	Rat	Cortical	Astrocytes		 +	 +	 NA	 [217]	Primary	Mouse	Cortical	Astrocyte		 +	 +	 NA	 [218]	Primary	Mouse	Cortical	Astrocytes		 NA	 +	 NA	 [271]	(-):	although	these	papers	claim	to	have	no	‘detectable	microglia’,	this	author	is	not	aware	of	any	protocol	to	date	that	
generates	pure	astrocyte	cultures	completely	absent	of	microglia.		NA:	not	applicable.	•NO	is	generated	by	activated	macrophages,	endothelial	cells,	and	hepatocytes	whereby	it	is	rapidly	transformed	into	various	reactive	nitrogen	intermediates	or	reactive	nitrogen/oxygen	intermediates	that	are	thought	to	have	direct	microbicidal/tumoricidal	effects.		•NO	is	also	known	to	induce	localized	vasodilation,	vascular	damage	and	increase	leukocyte	adhesion	and	infiltration	during	inflammatory	processes.		Upon	their	activation,	both	microglia	and	astrocytes	generate	the	soluble	enzyme	inducible	nitric	oxide	synthase	(iNOS)	which	catalyzes	L-arginine	to	form	•NO	in	the	extracellular	milieu.		Once	secreted,	gaseous	•NO	is	quickly	oxidized	primarily	into	nitrite	(NO2-)	at	physiological	pH,	where	it	can	remain	stable	for	several	hours—and	thus	can	be	measured	using	Greiss	reagent	as	an	accurate	proxy	for	the	generation	of	•NO.		The	co-administration	of	L-N(G)-nitroarginine,	a	selective	inhibitor	of	NOS,	was	capable	of	rescuing	DAnergic	neurons	from	LPS	in	vitro	and	in	vivo—implicated	that	•NO	or	its	intermediates	are	responsible	for	inflammation-mediated	neurodegeneration	[272,	273].		Interestingly,	our	laboratory	has	published	similar	findings	with	regards	to	the	generation	of	the	reactive	oxygen	species	superoxide	(O2•−)	by	NAD(P)H	oxidase	(NOX).		The	co-administration	of	selective	NOX	inhibitors	and	the	use	of	NOX2-deficient	mice	were	also	able	to	protect	DAnergic	neurons	from	LPS	in	vitro	and	in	vivo—suggesting	that	although	O2•−	and	•NO	may	be	themselves	cytotoxic,	their	fused	reactive	nitrogen	intermediate	products	may	significantly	contribute	to	inflammation-mediated	neurodegeneration.		Products	such	as	peroxynitrite	(ONOO−),	nitrite(•NO2),	and	














Primary	Rat	Cortical	Astrocyte		 +	 -	 NA	 [275]	Primary	Rat	Cortical	Astrocyte	 NA	 +	 NA	 [276]	Primary	Rat	Cortical	Astrocyte		 +	 +	 NA	 [277]	Primary	Rat	Cortical	Astrocyte	 +	 +	 +	 [278]	Primary	Whole	Brain	Astrocyte		 +	 +	 +/-	 [274]	Primary	Rat	Cortical	Mixed	Glia	 +	 -	 -	 [279]	Primary	Rat	Cortical	Astrocyte		 (-)	 -	 NA	 [279]	Primary	Rat	Cortical	Mixed	Glia	 +	 -	 -	 [280]	Primary	Rat	Spinal	Cord	Astrocytes	 (-)	 +	 +	 [281]	Primary	Mouse	Cortical	Mixed	Glia	 +	 -	 -	 [216]	Primary	Mouse	Cortical	Astrocyte	 +	 +	 NA	 [218]	Primary	Mouse	Cortical	Astrocyte	 +	 +	 -	 [282]	Primary	Mouse	Cortical	Mixed	Glia	 +	 -	 -	 [239]	Primary	Rat	Cortical	Astrocyte		 +	 +	 NA	 [271]	(-):	although	these	papers	claim	to	have	no	‘detectable	microglia’,	this	author	is	not	aware	of	any	protocol	to	date	that	
generates	pure	astrocyte	cultures	completely	absent	of	microglia.	NA:	not	applicable.	


























































Table	2.1	Target	genes	and	their	respective	mRNA	primer	sequences.	Primer	 GeneBank	ID	 Sequence	(5’→3’)	Rat	Iba-1	 		 NM_017196	 TTT	CTG	AGT	TGC	CCT	AAT	TGG	AG		(forward)	GCT	GTC	ATT	AGA	AGG	TCC	TCG	G		(reverse)	Rat	iNOS	 NM_012611	 GAG	TGA	GGA	GCA	GGT	TGA	GGA	TTA	C	(forward)	AGG	AAA	AGA	CCG	CAC	CGA	AG	(reverse)	Rat	TNFα	 NM_012675	 CCA	GAC	CCT	CAC	ACT	CAG	ATC	ATC	(forward)	CCT	CCG	CTT	GGT	GGT	TTG	CT	(reverse)	Rat	GDNF	 NM_019139	 CAG	AGG	GAA	AGG	TCG	CAG	AGG	(forward)	TAG	CCC	AAA	CCC	AAG	TCA	GTG	(reverse)	Rat	BDNF	 NM_012513	 CGA	TGC	CAG	TTG	CTT	TGT	CTT	C	(forward)	AAG	TTC	GGC	TTT	GCT	CAG	TGG	(reverse)	Mouse	GDNF	 NM_010275	 GGC	TGA	CCT	TGA	ACT	TAC	TGC	TTG	(forward)	CCT	GTG	GAT	ACG	GTG	TGA	TTG	AT	(reverse)	Mouse/Rat	GAPDH	(internal	control)	 NM_008084	NM_017008	 TTC	AAC	GGC	ACA	GTC	AAG	GC		(forward)	GAC	TCC	ACG	ACA	TAC	TCA	GCA	CC		(reverse)	
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